Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Recruiting 4Active not recruiting 4Terminated 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Multiple Myeloma 1

Interventions

pembrolizumab 75Carboplatin 61Cyclophosphamide 58Nivolumab 50Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 35Rituximab 32Capecitabine 31Docetaxel 29Bevacizumab 29fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Fluorouracil 22Azacitidine 22Temozolomide 21Ipilimumab 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × dostarlimab × Clear all
NCT04926324 2025-06-29

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

University of Iowa

Phase 1/2 Terminated
3 enrolled
Gastrointestinal

Rectal Neoplasms

NCT06655818 2025-03-03

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

GlaxoSmithKline

Phase 1/2 Terminated
4 enrolled 16 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡